NCT02452632View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

June 22, 2015

Primary Completion Date

January 5, 2017

Study Completion Date

January 5, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ASP1941

oral

DRUG

Placebo

oral

Trial Locations (22)

Unknown

Site KR00019, Dong Gu Gwangju

Site KR00008, Gangwon-do

Site KR00020, Jeollabuk-do

Site KR00021, Kyungsangnam-do

Site KR00002, Busan

Site KR00003, Busan

Site KR00007, Daegu

Site KR00011, Daegu

Site KR00018, Gyeonggi-do

Site KR00022, Gyeonggi-do

Site KR00014, Incheon

Site KR00001, Seoul

Site KR00004, Seoul

Site KR00005, Seoul

Site KR00006, Seoul

Site KR00009, Seoul

Site KR00010, Seoul

Site KR00012, Seoul

Site KR00013, Seoul

Site KR00016, Seoul

Site KR00017, Seoul

Site KR00015, Suwon

All Listed Sponsors
lead

Astellas Pharma Korea, Inc.

INDUSTRY

NCT02452632 - A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin | Biotech Hunter | Biotech Hunter